OSE Immunotherapeutics Expands Program Around Lusvertikimab
OSE Immunotherapeutics announces the selection of two new clinical indications for lusvertikimab (OSE-127): chronic pouchitis and hidradenitis suppurativa. This decision is part of the Company's 2026-2028 strategic plan, aimed at expanding the use of the drug candidate for targeted autoimmune diseases.
Chronic pouchitis and hidradenitis suppurativa were chosen due to their biological rationale with IL-7R, the target of lusvertikimab. These two indications are part of the 2026-2028 strategic plan aimed at expanding the use of lusvertikimab for targeted autoimmune diseases. The Company aims for a balanced diversification strategy: chronic pouchitis as a short-term rare disease, hidradenitis suppurativa in dermatology in the medium term, complemented by the existing program in ulcerative colitis.
Initiation of Clinical Trials and Partnership Plans
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The start of a first Phase 2 clinical trial is scheduled for the second half of 2026, subject to funding. Concurrently, OSE will transition its ulcerative colitis indication to a subcutaneous formulation of lusvertikimab and aims to establish a partnership once bioequivalence data are obtained. Additional scientific data will be generated to validate a potentially predictive biomarker identified in the Phase 2 CoTikiS study.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
